| Ticker Details |
Veracyte, Inc.
Veracyte Inc is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The Company's first commercial solution, the Afirma Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier.
|
| IPO Date: |
October 30, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.82B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.58 | 2.52%
|
| Avg Daily Range (30 D): |
$0.78 | 1.97%
|
| Avg Daily Range (90 D): |
$0.82 | 2.00%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.4M |
| Avg Daily Volume (30 D): |
.62M |
| Avg Daily Volume (90 D): |
.66M |
| Trade Size |
| Avg Trade Size (Sh.): |
62 |
| Avg Trade Size (Sh.) (30 D): |
49 |
| Avg Trade Size (Sh.) (90 D): |
48 |
| Institutional Trades |
| Total Institutional Trades: |
3,586 |
| Avg Institutional Trade: |
$2.77M |
| Avg Institutional Trade (30 D): |
$4M |
| Avg Institutional Trade (90 D): |
$3.74M |
| Avg Institutional Trade Volume: |
.09M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.09M |
| Avg Closing Trade (30 D): |
$6.88M |
| Avg Closing Trade (90 D): |
$6.8M |
| Avg Closing Volume: |
135.69K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$.24
|
$-.01
|
|
Diluted EPS
|
|
$.24
|
$-.01
|
|
Revenue
|
|
$131.87M
|
$130.16M
|
|
Gross Profit
|
|
$91.28M
|
$89.77M
|
|
Net Income / Loss
|
|
$19.14M
|
$-.98M
|
|
Operating Income / Loss
|
|
$22.95M
|
$-5.27M
|
|
Cost of Revenue
|
|
$40.59M
|
$40.4M
|
|
Net Cash Flow
|
|
$96.06M
|
$33.39M
|
|
PE Ratio
|
|
|
|
|
|
|
